

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 6185)**

**INSIDE INFORMATION**

**DETERMINATION OF THE OFFER SIZE AND ISSUE PRICE  
FOR THE ISSUE OF A SHARES**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

References are made to the Company’s announcements dated October 14, 2019, January 22, 2020, February 3, 2020, March 19, 2020, April 14, 2020, April 21, 2020, May 4, 2020, May 8, 2020, May 10, 2020, July 15, 2020, July 16, 2020, July 23, 2020, circular dated October 14, 2019 and supplemental circular dated November 14, 2019 containing, among other things, related matters of the proposed initial public issue of A Shares (the “**Proposed Issue of A Shares**”) and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcements and the circular.

The board of directors of the Company (the “**Board**”) is pleased to announce that, following the completion of preliminary price consultations among inquiry targets on July 28, 2020, the Company will issue 24,800,000 A Shares at the issue price of RMB209.71 per A Share. The issue price was determined based on several factors including, among others, results of the preliminary price consultation, the number of A Shares to be issued, the fundamentals of the issuer, valuation of comparable companies, the industry in which the Company operates, market conditions and underwriting risks.

For the relevant terms of the Proposed Issue of A Shares, please refer to the full text of the Issue Announcement of CanSino Biologics Inc. for the Initial Public Offering and Listing of Stocks on the Sci-Tech Innovation Board (《康希諾生物股份公司首次公開發行股票並在科創板上市發行公告》) published by the Company in Chinese only on the website of Shanghai Stock Exchange ([www.sse.com.cn](http://www.sse.com.cn)), the website of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the website of the Company ([www.cansinotech.com](http://www.cansinotech.com)) on July 30, 2020.

**Further announcement(s) regarding the details and developments of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement appears for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.**

By Order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, July 30, 2020

*As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.*